REAL-WORLD DATA SUGGEST EFFECTIVNESS OF THE ALLOGENEIC MESENCHYMAL STROMAL CELLS PREPARATION MSC-FFM IN RUXOLITINIB-REFRACTORY OR -INTOLERANT ACUTE GRAFT-VERSUS-HOST DISEASE
Acute graft-versus-host disease (aGvHD) remains the leading cause of treatment-related morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Current first-line treatment of aGvHD is with high-dose corticosteroids. The standard for steroid-refractory aGvHD (SR-aGvHD) is th...
Saved in:
Published in | Cytotherapy (Oxford, England) Vol. 26; no. 6; p. S24 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
01.06.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Acute graft-versus-host disease (aGvHD) remains the leading cause of treatment-related morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Current first-line treatment of aGvHD is with high-dose corticosteroids. The standard for steroid-refractory aGvHD (SR-aGvHD) is the Janus kinase inhibitor ruxolitinib.
Outcomes for patients with ruxolitinib-refractory or -intolerant aGvHD (RR-aGvHD) are poor. In a recent real-world study of adult patients with RR-aGvHD (Abedin Br J Haematol 2021 Nov;195(3):429-432.) median survival was 28 days, and the probabilities of overall survival (OS) at 6, 12, and 24 months were 20%, 16%, and 10%, respectively.
We assessed real-world outcomes of patients with RR-aGvHD treated with the random-donor allogeneic MSC preparation MSC-FFM available via Hospital Exemption in Germany.
Between December 2017 and February 2023, 156 patients, 33 children and adolescents and 123 adults, received MSC-FFM for RR-aGvHD. Overall, 32 German sites contributed 139 patients, while the remaining patients came from France, Hungary, Norway, Sweden, and Switzerland.
MSC-FFM is manufactured from pooled bone marrow mononuclear cells from eight HLA-disparate healthy donors. MSCs are selected by plastic adherence, expanded in platelet lysate-enriched media in 2D culture until the end of passage 3, then frozen in saline-albumin with DMSO. Manufacturing is according to GMP and all applicable laws and regulations. The recommended dosing for MSC-FFM is 1-2x106 cells/kg body weight (BW), for four weekly doses. The median dose administered was 1.18x106 cells/kg BW, with a median number of four doses and a median inter-dose interval of 7 days.
Tolerability of MSC-FFM was good, with only five adverse drug reactions reported in three adult patients, which did not result in cessation of MSC treatment or dose reductions.
The overall response rate (ORR) at day +28 after the first dose was 49%, with 45% in adults and 64% in children. Most responses were durable, resulting in an ORR of 49% for both adults and children at 2 months, and 40% at 6 months after start of treatment.
OS at 6, 12, and 24 months was 47%, 35%, and 30% for adults, and 59%, 42%, and 35% for children, respectively. After a median follow-up of 26.7 month, median OS was 5.8 months. These outcomes compare favourably to published OS estimates for adult RR-aGvHD patients not treated with MSC-FFM (Abedin BJH).
The unique MSC-preparation MSC-FFM appears to be effective against RR-aGvHD. |
---|---|
AbstractList | Acute graft-versus-host disease (aGvHD) remains the leading cause of treatment-related morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Current first-line treatment of aGvHD is with high-dose corticosteroids. The standard for steroid-refractory aGvHD (SR-aGvHD) is the Janus kinase inhibitor ruxolitinib.
Outcomes for patients with ruxolitinib-refractory or -intolerant aGvHD (RR-aGvHD) are poor. In a recent real-world study of adult patients with RR-aGvHD (Abedin Br J Haematol 2021 Nov;195(3):429-432.) median survival was 28 days, and the probabilities of overall survival (OS) at 6, 12, and 24 months were 20%, 16%, and 10%, respectively.
We assessed real-world outcomes of patients with RR-aGvHD treated with the random-donor allogeneic MSC preparation MSC-FFM available via Hospital Exemption in Germany.
Between December 2017 and February 2023, 156 patients, 33 children and adolescents and 123 adults, received MSC-FFM for RR-aGvHD. Overall, 32 German sites contributed 139 patients, while the remaining patients came from France, Hungary, Norway, Sweden, and Switzerland.
MSC-FFM is manufactured from pooled bone marrow mononuclear cells from eight HLA-disparate healthy donors. MSCs are selected by plastic adherence, expanded in platelet lysate-enriched media in 2D culture until the end of passage 3, then frozen in saline-albumin with DMSO. Manufacturing is according to GMP and all applicable laws and regulations. The recommended dosing for MSC-FFM is 1-2x106 cells/kg body weight (BW), for four weekly doses. The median dose administered was 1.18x106 cells/kg BW, with a median number of four doses and a median inter-dose interval of 7 days.
Tolerability of MSC-FFM was good, with only five adverse drug reactions reported in three adult patients, which did not result in cessation of MSC treatment or dose reductions.
The overall response rate (ORR) at day +28 after the first dose was 49%, with 45% in adults and 64% in children. Most responses were durable, resulting in an ORR of 49% for both adults and children at 2 months, and 40% at 6 months after start of treatment.
OS at 6, 12, and 24 months was 47%, 35%, and 30% for adults, and 59%, 42%, and 35% for children, respectively. After a median follow-up of 26.7 month, median OS was 5.8 months. These outcomes compare favourably to published OS estimates for adult RR-aGvHD patients not treated with MSC-FFM (Abedin BJH).
The unique MSC-preparation MSC-FFM appears to be effective against RR-aGvHD. |
Author | Verbeek, M. Schrezenmeier, H. Kuci, S. von Stackelberg, A. Schmid, C. Jahrsdorfer, B. Kuci, Z. Holtick, U. Pfeffermann, L. Huenecke, S. Zens, A. Bug, G. Braitsch, K. Beutel, G. Wulf, G. Tischer, J. Herhaus, P. Boenig, H.B. Ayuk, F. Döring, M. Tribanek, M. Muller, N. Zeiser, R. Bader, P. |
Author_xml | – sequence: 1 givenname: L. surname: Pfeffermann fullname: Pfeffermann, L. organization: DRK Blutspendedienst Baden-Wurttemberg - Hessen, Frankfurt am Main, Hessen, Germany – sequence: 2 givenname: H.B. surname: Boenig fullname: Boenig, H.B. organization: DRK Blutspendedienst Baden-Wurttemberg - Hessen, Frankfurt am Main, Hessen, Germany – sequence: 3 givenname: M. surname: Verbeek fullname: Verbeek, M. organization: Clinic and Policlinic for Internal Medicine III, Klinikum rechts der Isar der Technischen Universitat Munchen, Munchen, Bayern, Germany – sequence: 4 givenname: P. surname: Herhaus fullname: Herhaus, P. organization: Clinic and Policlinic for Internal Medicine III, Klinikum rechts der Isar der Technischen Universitat Munchen, Munchen, Bayern, Germany – sequence: 5 givenname: K. surname: Braitsch fullname: Braitsch, K. organization: Clinic and Policlinic for Internal Medicine III, Klinikum rechts der Isar der Technischen Universitat Munchen, Munchen, Bayern, Germany – sequence: 6 givenname: G. surname: Beutel fullname: Beutel, G. organization: Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany – sequence: 7 givenname: C. surname: Schmid fullname: Schmid, C. organization: Augsburg University Hospital and Medical Faculty, Augsburg, Germany – sequence: 8 givenname: N. surname: Muller fullname: Muller, N. organization: Universitatsklinikum Mannheim, Mannheim, Baden-Württemberg, Germany – sequence: 9 givenname: G. surname: Bug fullname: Bug, G. organization: Department of Medicine 2, Klinikum der Johann Wolfgang Goethe-Universitat Frankfurt, Frankfurt am Main, Hessen, Germany – sequence: 10 givenname: M. surname: Döring fullname: Döring, M. organization: Department I-General Pediatrics, Hematology and Oncology, Universitatsklinikum Tubingen, Tubingen, Baden-Württemberg, Germany – sequence: 11 givenname: A. surname: von Stackelberg fullname: von Stackelberg, A. organization: Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany – sequence: 12 givenname: J. surname: Tischer fullname: Tischer, J. organization: Department of Medicine III, Ludwig-Maximilians-Universitat Munchen, Munchen, Bayern, Germany – sequence: 13 givenname: F. surname: Ayuk fullname: Ayuk, F. organization: Klinik Für Stammzelltransplantation, Universitatsklinikum Hamburg-Eppendorf, Hamburg, Hamburg, Germany – sequence: 14 givenname: G. surname: Wulf fullname: Wulf, G. organization: Hämatologie Und Medizinische Onkologie, Universitatsmedizin Gottingen, Gottingen, Niedersachsen, Germany – sequence: 15 givenname: U. surname: Holtick fullname: Holtick, U. organization: Department I of Internal Medicine, Medical Faculty and University Hospital of Cologne, Cologne, Germany – sequence: 16 givenname: B. surname: Jahrsdorfer fullname: Jahrsdorfer, B. organization: Institute for Clinical Transfusion Medicine and Immunogenetics, University of Ulm, Ulm, Germany – sequence: 17 givenname: H. surname: Schrezenmeier fullname: Schrezenmeier, H. organization: Institute for Clinical Transfusion Medicine and Immunogenetics, University of Ulm, Ulm, Germany – sequence: 18 givenname: S. surname: Kuci fullname: Kuci, S. organization: Division for Stem Cell Transplantation and Immunology, University Hospital for Children and Adolescents, Frankfurt am Main, Germany – sequence: 19 givenname: Z. surname: Kuci fullname: Kuci, Z. organization: Division for Stem Cell Transplantation and Immunology, University Hospital for Children and Adolescents, Frankfurt am Main, Germany – sequence: 20 givenname: A. surname: Zens fullname: Zens, A. organization: medac Gesellschaft fur klinische Spezialpraparate mbH, Wedel, Schleswig-Holstein, Germany – sequence: 21 givenname: M. surname: Tribanek fullname: Tribanek, M. organization: medac Gesellschaft fur klinische Spezialpraparate mbH, Wedel, Schleswig-Holstein, Germany – sequence: 22 givenname: R. surname: Zeiser fullname: Zeiser, R. organization: Department Innere Medizin, Klinik Für Innere Medizin I, Universitatsklinikum Freiburg, Freiburg, Baden-Württemberg, Germany – sequence: 23 givenname: S. surname: Huenecke fullname: Huenecke, S. organization: Department of Pediatrics, Division of Stem Cell Transplantation and Immunology, Goethe-Universitat Frankfurt am Main, Frankfurt am Main, Hessen, Germany – sequence: 24 givenname: P. surname: Bader fullname: Bader, P. organization: Department of Pediatrics, Division of Stem Cell Transplantation and Immunology, Goethe-Universitat Frankfurt am Main, Frankfurt am Main, Hessen, Germany |
BookMark | eNp9kMFq3DAYhE1JoUnaF-hJL6CtLMuyDb2o2t-7Aq8VJG3anMTaksFLu1vsEMhD9R1rk54LA_NfvmH-uUtuLtdLTJLPKdmkJOVfzptz__q8oYSyDckWle-S25QVBaY55zfrzXOcUVZ9SO7m-UwIJWWZ3yZ_DIgGf9em2aKtcALZ424H1iGoa5BOPbZgLdI1cntAomn0DlpQEh3AQiv3TwfRIOuMXl1C01j0YOBBGOGUbtHBSlzXB6RaZI4_dKOcatU3bKA2QjptnpA2CKvW6QaMaB0S8ugA7YyoHX4EY48W7_XSZqssCAsfk_fD6eccP_3z-8TV4OQeL72UXB7pK17igkUWeHYKIdCSsbTjrAtDDCXtTqTrYhUYKXhXsZTnLO-KQAirBt4XgVddR4fsPqFvsf10necpDv73NP46Ta8-JX7d25_9urdf9_YkW1Qu0Nc3KC7FXsY4-bkf46WPYZxi_-zDdfwf_hfZXH9o |
ContentType | Journal Article |
Copyright | 2024 |
Copyright_xml | – notice: 2024 |
DBID | AAYXX CITATION |
DOI | 10.1016/j.jcyt.2024.03.038 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1477-2566 |
EndPage | S24 |
ExternalDocumentID | 10_1016_j_jcyt_2024_03_038 S1465324924001269 |
GroupedDBID | --- --M .1- .FO .~1 1P~ 1~. 29F 36B 4.4 457 4G. 53G 5GY 5VS 7-5 8P~ AAAJQ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAXUO ABDBF ABGSF ABJNI ABMAC ABMZM ABUDA ABXDB ACDAQ ACGEJ ACGFS ACRLP ADBBV ADCVX ADEZE ADXPE AEBSH AEHWI AEKER AENEX AEVXI AFCTW AFKVX AFKWA AFRHN AFTJW AFXIZ AGEKW AGHFR AGRDE AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AJWEG AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AWYRJ AXJTR AZFZN BKOJK BLXMC BNPGV CAG CJTIS COF CS3 DU5 EAP EBC EBS EFJIC EJD EMB EMK EMOBN ESX F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM LUGTX M44 MO0 O-L O9. OAUVE OK~ P-8 P-9 P2P PC. Q38 R2- ROL SDF SPCBC SSH SSI SSU SSZ SV3 T5K TFW Z5R ~G- AAXKI AAYXX AFJKZ CITATION H13 TDBHL |
ID | FETCH-LOGICAL-c968-74e4d63addd28441b64bdfed82ba0bbe9d4076b9416545b7d0049f6c7d69bb2f3 |
IEDL.DBID | AIKHN |
ISSN | 1465-3249 |
IngestDate | Thu Sep 26 21:36:10 EDT 2024 Sat Jun 29 15:31:21 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | aGvHD MSC Ruxolitinib |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c968-74e4d63addd28441b64bdfed82ba0bbe9d4076b9416545b7d0049f6c7d69bb2f3 |
ParticipantIDs | crossref_primary_10_1016_j_jcyt_2024_03_038 elsevier_sciencedirect_doi_10_1016_j_jcyt_2024_03_038 |
PublicationCentury | 2000 |
PublicationDate | June 2024 2024-06-00 |
PublicationDateYYYYMMDD | 2024-06-01 |
PublicationDate_xml | – month: 06 year: 2024 text: June 2024 |
PublicationDecade | 2020 |
PublicationTitle | Cytotherapy (Oxford, England) |
PublicationYear | 2024 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
SSID | ssj0020885 |
Score | 2.4356372 |
Snippet | Acute graft-versus-host disease (aGvHD) remains the leading cause of treatment-related morbidity and mortality after allogeneic hematopoietic stem cell... |
SourceID | crossref elsevier |
SourceType | Aggregation Database Publisher |
StartPage | S24 |
SubjectTerms | aGvHD MSC Ruxolitinib |
Title | REAL-WORLD DATA SUGGEST EFFECTIVNESS OF THE ALLOGENEIC MESENCHYMAL STROMAL CELLS PREPARATION MSC-FFM IN RUXOLITINIB-REFRACTORY OR -INTOLERANT ACUTE GRAFT-VERSUS-HOST DISEASE |
URI | https://dx.doi.org/10.1016/j.jcyt.2024.03.038 |
Volume | 26 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELba7YULggLiWc0B9ULNdhPHuzmarLMJ5LGynbI9RfE6kdrDUkE57IV_xH_EbrItSKiHSpHyUCxZHnu-GWu-zwi994xHg6Bp8dRMbIISNjO75kKKO68JdddZiF67rYG8oElFPq-C1R6KdlwYV1Y5-P7ep9946-HLeBjN8dXFxVhOnDSYE7wjDrNpuI8OLBwRMkIHLP2SFLd5l11IQU8yCrBrMHBn-jKvy_XWlVR65Ebr1NFU_odPf2FO_AQ9HoJFYH1_nqK9dnOIjpe92vT2BNQdeerHCRzD8k6HevsM_RacZfhrKbI5zJliIKvFgksFNjblkUrP3HkbUMagEg4sy0pXxpZGkHPJiyg5z1kGUonS3SOeZRKsuZas39WCXEY4jnNICxDVqsxSlRbpJyx4LFikSnEOpQCcFqrMuGCFAhZVisNCsFjhMy5kJXFS2t7MU8mZ5M-RirmKEjyczoDXIXUapC0x1Lfu0ViEIxNNiTZda2aebk61bkNjU0WqQ-LoUoGeGpeLdHQ9NTTU2uv8F2i0-bZpXyJwbNjWpsrGBC3xZ9PGI_a58W10qD1jZq_Qh51J6qteg6PeFadd1s6AtTNgferby_4d7KxW_zOTagsS97R7_cB2b9Aj99aXj71Fo-vvP9t3NlC51kdo_-OvydEwHf8Aoj7bfA |
link.rule.ids | 315,786,790,4521,24144,27955,27956,45618,45712 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjtMwFLWGYQEbxFMMz7tAs2FMp3m1WZrUaQJOUtnu0FlFcZ1IM4sygmHRDX_EP-LbpAxIiAVSpESJLVm59n1Y5xwT8sazXhSGTUsnduwKlLiZujUXR7Tzmth0nQvRa9waKMooWwYfVuHqgCR7LgzCKgff3_v0nbce3oyGvzm6urgYqTFKg6HgXYAxO4pvkduYDSCu6933XzgPzy2jsKcYhRSbD8yZHuR1ud4ioNILdkqnSFL5W3T6LeKk98m9IVUE1o_mATloNw_J8aLXmt6egL6hTn09gWNY3KhQbx-RH5IzQT9VUsxgxjQDtZzPudLgMlOe6PwMT9uAKgWdcWBCVAhiyxMouOJlkp0XTIDSssJ7woVQ4Iy1YP2eFhQqoWlaQF6CXK4qkeu8zN9TyVPJEl3Jc6gk0LzUleCSlRpYstQc5pKlmp5xqZaKZpUbzSxXnCn-mOiU6ySjw9kMdB1HqEDaBjbynXO0Lr4FYxMFxnatnXqmOTWmja0rFCMTB0iWCs3EYiXSReuJjWJjvM5_Qg43nzftUwLIhW1doWxt2Ab-dNJ4gXtufJcbGs_a6RF5uzdJfdUrcNR7aNpljQas0YD1qe8u1zrcW63-Yx7VLkT8o9-z_-z3mtzJdCFqkZcfn5O7-KUHkr0gh9dfvrUvXcpybV7tpuRPf9_cUQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=REAL-WORLD+DATA+SUGGEST+EFFECTIVNESS+OF+THE+ALLOGENEIC+MESENCHYMAL+STROMAL+CELLS+PREPARATION+MSC-FFM+IN+RUXOLITINIB-REFRACTORY+OR+-INTOLERANT+ACUTE+GRAFT-VERSUS-HOST+DISEASE&rft.jtitle=Cytotherapy+%28Oxford%2C+England%29&rft.au=Pfeffermann%2C+L.&rft.au=Boenig%2C+H.B.&rft.au=Verbeek%2C+M.&rft.au=Herhaus%2C+P.&rft.date=2024-06-01&rft.pub=Elsevier+Inc&rft.issn=1465-3249&rft.eissn=1477-2566&rft.volume=26&rft.issue=6&rft.spage=S24&rft.epage=S24&rft_id=info:doi/10.1016%2Fj.jcyt.2024.03.038&rft.externalDocID=S1465324924001269 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-3249&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-3249&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-3249&client=summon |